Centenara Labs

Centenara Labs is a pioneering longevity-focused biotech that builds and invests in a diversified portfolio of companies targeting geriatric diseases through the lens of aging biology. Its strategy involves de-risking early scientific discoveries by providing a platform of experienced drug developers, business leaders, and capital. With a pipeline built around the hallmarks of aging, the company has progressed two ophthalmology programs into the clinic and is advancing several pre-clinical assets in fibrosis, cancer, and sarcopenia, aiming to create optimal exit scenarios to fund new ventures.

A portfolio and investment model focused on translating the 'Hallmarks of Aging' framework into drug development. It identifies, founds, and invests in early-stage companies targeting primary, antagonistic, and integrative aging pathways.

Competes with other longevity biotechs (e.g., Unity Biotechnology) and large pharma exploring aging pathways. Differentiates through its diversified portfolio company model, which spreads risk and leverages a structured investment thesis based on the hallmarks of aging, rather than focusing on a single technology.